Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

89.64 +1.02 (+1.15%)
Streaming Delayed Price Updated: 2:23 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,928,910
Open 89.06
Bid (Size) 89.63 (8)
Ask (Size) 89.66 (8)
Prev. Close 88.63
Today's Range 88.07 - 89.94
52wk Range 62.07 - 98.90
Shares Outstanding 1,253,809,440
Dividend Yield 3.35%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
26 Analysts Assess Gilead Sciences: What You Need To Know
Via Benzinga
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety. 
Via Benzinga

Performance

YTD
+7.69%
+7.69%
1 Month
+3.89%
+3.89%
3 Month
+19.32%
+19.32%
6 Month
+32.22%
+32.22%
1 Year
+20.02%
+20.02%

More News

Read More
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low
Via Benzinga
Topics Government
Exposures Political
3 Healthcare Stocks For Long-Term Growth And Dividends
Via Talk Markets
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Gilead Sciences's Earnings: A Preview
Via Benzinga
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
Via ACCESSWIRE
Gilead Prices $3.5 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
From Gilead Sciences, Inc.
Via Business Wire
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
3 Spectacular High-Yield Dividend Stocks to Buy in November
Via The Motley Fool
Gilead Sciences to Present at Upcoming Investor Engagements
From Gilead Sciences, Inc.
Via Business Wire
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
Via Benzinga
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
Via Benzinga
Topics Earnings
Exposures Financial
Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Gilead’s Stock Surge: What’s Fueling the Momentum?
Via MarketBeat
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Gilead Sciences Announces Third Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales
Via Investor's Business Daily
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
From Gilead Sciences, Inc.
Via Business Wire
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.